Palantir stock continues to crush the broader market, but can the company sustain these gains over the next several months?

AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

Alphabet stock rose only slightly yesterday despite the company posting stellar Q2 results. Here’s what drove the divergence ...

Two companies have recently seen their stock prices head higher on optimism about the future growth in AI spending. Palantir ...

Analysts are intrested in these 5 stocks: ( ($PLTR) ), ( ($HPE) ), ( ($CVNA) ), ( ($NDAQ) ) and ( ($DOW) ). Here is a breakdown of their recent ...

Key Points Despite being overvalued, Palantir stock continues to rise. How much longer can the bull run last?10 stocks we like better than Palantir Technologies › Even though its stock price has more ...

Lear Corp (LEA) reports $6 billion in revenue and strategic partnerships, while navigating macroeconomic uncertainties and ...

Although Palantir posted strong earnings results in Q1, 39% revenue growth normally doesn't justify the stock doubling.